Drug
Molidustat clinical trials
Also written BAY85-3934.
- studies test it
- 15
- open now
- 0
- in phase 3
- 5
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
15 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Studies
Open first, then newest update. How each study uses molidustat is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Study of Molidustat for Correction of Renal Anemia in Dialysis SubjectsCompletedPhase 3BayerNCT03351166Written as Molidustat (BAY85-3934)
- A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis SubjectsCompletedPhase 3BayerNCT03418168Written as Molidustat (BAY85-3934)
- Maintenance Treatment of Renal Anemia in Dialysis SubjectsCompletedPhase 3BayerNCT03543657Written as Molidustat (BAY85-3934)
- A Study of Molidustat for Correction of Renal Anemia in Non-dialysis SubjectsCompletedPhase 3BayerNCT03350321Written as Molidustat (BAY85-3934)
- A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis SubjectsCompletedPhase 3BayerNCT03350347Written as Molidustat (BAY85-3934)
- Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched SubjectsCompletedPhase 1BayerNCT01318551Written as BAY85-3934
- To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy SubjectsCompletedPhase 1BayerNCT02312973Written as Molidustat(BAY85-3934)
- Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934CompletedPhase 2BayerNCT02064426Written as Molidustat (BAY85-3934)
- Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934CompletedPhase 2BayerNCT01975818Written as Molidustat (BAY 85-3934)
- 15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)CompletedPhase 2BayerNCT02021370Written as BAY85-3934
- Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934CompletedPhase 2BayerNCT02021409Written as BAY85-3934
- Long-term Pre-dialysis Extension in Europe and Asia PacificCompletedPhase 2BayerNCT02055482Written as Molidustat (BAY85-3934)
- Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)CompletedPhase 1BayerNCT01679587Written as Molidustat (BAY85-3934)
- Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)CompletedPhase 1BayerNCT01332942Written as BAY85-3934
- Age and Gender Effects on the Pharmacokinetics of BAY85-3934CompletedPhase 1BayerNCT01458028Written as BAY85-3934
Codes
What other systems call molidustat · ClinicalTrials.gg INT000369
- MeSH (NLM) C000603972molidustatOne source NLM
- UNII (FDA) 9JH486CZ13MOLIDUSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27087553molidustatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174580MolidustatOne source FDA
- DrugBank DB15642One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000603972 | molidustat | One source NLM |
| UNII (FDA) | 9JH486CZ13 | MOLIDUSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27087553 | molidustat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174580 | Molidustat | One source FDA |
| DrugBank | DB15642 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.